David N. Hurst

Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy

Adrian Hall, Andy Billinton, Susan H. Brown et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 76 citations · Full text

Health Sciences, Pain Medicine, Medicine +9

The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain

Gerard M.P. Giblin, Rino A. Bit, Susan H. Brown et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 47 citations · Full text

Inflammation, Medicinal Chemistry, Anti-inflammatory +13

Individualizing theophylline therapy: the impact of clinical pharmacokinetics on patient outcomes.

Dennis Mungall, James D. Marshall, Dennis Penn et al. · PubMed · 1983 · 41 citations

Therapeutic Drug Monitoring, Clinical Therapeutic, Clinical Pharmacokinetics Service +12

Discovery of novel low molecular weight inhibitors of IMPDH via virtual needle screening

Stephen D. Pickett, Bradley Sherborne, Trevor Wilkinson et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 37 citations · Full text

Virtual Needle Screening, Medicinal Chemistry, Pharmaceutical Research +11

.beta.-Adrenoceptor activity of the stereoisomers of the bufuralol alcohol and ketone metabolites

Peter J. Machin, David N. Hurst, J. M. Osbond · Journal of Medicinal Chemistry · 1985 · 32 citations